Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Chronic hepatitis C genotype 1. GT-1b Capped at 50 % of naïve subjects
Naives to prior anti-HCV therapy \[Interferon (IFN) and direct antiviral agent (DAA) based\]
Relapsers (defined as subjects who had undetectable HCV ribonucleic acid (RNA) on prior treatment regimen of alfa-2a/RBV and Hepatitis C Virus (HCV) RNA \> 25IU/mL after discontinuation of treatment). Capped at 20%
HCV RNA ≥ 100,000 IU/mL
Subjects with compensated cirrhosis can be enrolled and will be capped at approximately 10%
Seronegative for human immunodeficiency virus (HIV) and hepatitis B surface antigen (HBsAg)
Men or women, 18-70 years of age
You may not be if
Chronic liver disease due to causes other than chronic HCV
Current or past evidence of decompensation
Conditions that preclude the use of Alfa/RBV/TVR per respective labels
